Le Lézard
Classified in: Health, Science and technology, Business
Subjects: ASI, CXP

Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia


BEIJING, July 19, 2018 /PRNewswire/ -- Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, today announced the grand opening of Anderson Biotech Company Limited and Royal OncoCare Hospitality as two wholly owned subsidiaries of Yisheng Biopharma in Cambodia. The two divisions represent the first expansion of Yisheng Biopharma business and product sales operations into an ASEAN member country.

"The opening of these two divisions is an important milestone in company history," commented Zhang Yi, Founder and Chairman of Yisheng Biopharma. "Our product YivykaTM is approved in Cambodia for the treatment of advanced solid tumors, including lung, breast, liver, colorectal and stomach cancers. We are pleased to be in a position to expand access to the benefits that this product will bring to cancer patients and are grateful for the support we have received from the Ministry of Health of the Kingdom of Cambodia."

"ASEAN countries have witnessed a significant economic boom over the last decade and represent one of the fastest growing markets for the biopharmaceutical industry," added David Shao, Ph.D., President and CEO of Yisheng Biopharma. "With a population of over 600 million under-served individuals in these countries, we are committed to expanding and deepening our presence in this region of southeast Asia. We are conducting drug development in this region, with programs in immuno-oncology, rabies and hepatitis B infection, and are well positioned to introduce a series of innovative products into this region."

YivykaTM is an innovative immuno-oncology drug recently granted a drug registration license by the Ministry of Health of the Kingdom of Cambodia. YivykaTM is the first biological product introduced into the Cambodia market by Yisheng Biopharma. 

About Yisheng Biopharma Co., Ltd.

Yisheng Biopharma is a global biopharmaceutical company discovering, developing and commercializing innovative immunological biologics. With approximately 700 employees worldwide and operations in China, the United States, Singapore and certain Southeast Asian countries. 

www.yishengbio.com

 

SOURCE Yisheng Biopharma Co., Ltd.


These press releases may also interest you

at 19:13
LG Energy Solution to Take Firm Stance Against Patent Infringers
A surge in patent infringement by latecomers in the battery industry, and subsequent market distortion caused by unlicensed use of patented technology, calls for strong countermeasures to level the playing fieldLG Energy Solution believes that at...

at 19:05
Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched...

at 19:00
Visionary Holdings Inc. Announcement of Management Change
Visionary Holdings Inc. (the "Company") , a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China, today announced on April 22, 2024, the...

at 19:00
Kansas Proving Grounds Partners with SkyScoutAI Innovations Inc. to Deploy AI-Powered Drones for Wildfire Solution at America's First Carbon Neutral Industrial Park
The Kansas Proving Grounds at Great Plains Industrial Park, a leading facility for testing and innovation, is proud to announce its partnership with SkyscoutAI Innovations Inc., a pioneer in AI-powered wildfire detection and response using drones and...

at 19:00
UST Strengthens Presence in the Australian Market with Strategic Acquisition of Leading Consulting Firm Strativity Group
UST, a leading digital transformation solutions company, today announced that it has acquired Strativity Group, a boutique strategy consultancy specialising in customer-centric transformations. Strativity is renowned for delivering customer...

at 18:45
IANS Research Receives Strategic Investment From the Apax Digital Funds to Accelerate Growth and Market Leadership in Information Security
IANS Research, the leading provider of independent research and advisory services for the information security industry, has announced a new strategic investment from the Apax Digital Fund II (the "Apax Digital Funds"). IANS is a widely recognized...

More news about Science and technology...


News published on and distributed by: